惠程科技(002168) - 2025 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2025 reached ¥104,462,682.39, a significant increase of 191.12% compared to the same period last year[4] - Net profit attributable to shareholders was -¥11,550,145.18, representing a decrease of 15.75% year-on-year[4] - The company reported a 93.13% increase in year-to-date revenue, totaling ¥284,255,362.94, primarily due to the addition of new pharmaceutical business segments[12] - The company’s basic earnings per share for Q3 2025 was -¥0.0147, a 16.00% improvement compared to the same period last year[4] - The net loss for the current period was ¥29,564,631.77, compared to a net loss of ¥84,621,133.38 in the previous period, indicating an improvement in financial performance[36] - The net profit attributable to shareholders of the parent company was a loss of ¥43,216,718.63, compared to a loss of ¥83,094,773.02 in the previous period, showing a reduction in losses[37] - The company reported a total comprehensive loss of ¥38,861,381.97 for the current period, compared to a loss of ¥88,385,794.44 in the previous period, indicating a narrowing of overall losses[37] - The basic and diluted earnings per share for the current period were both -0.0551, an improvement from -0.1060 in the previous period, reflecting better performance on a per-share basis[37] Cash Flow and Financial Position - The net cash flow from operating activities for the year-to-date period was ¥27,699,626.97, an increase of 128.69% compared to the previous year[14] - Cash flow from operating activities was ¥284,607,722.88, compared to ¥168,168,819.86 in the previous period, reflecting a strong increase in cash generation from operations[38] - Total cash inflow from operating activities amounted to $315,122,569.25, while cash outflow was $287,422,942.28, resulting in a positive cash flow[39] - The ending balance of cash and cash equivalents was $14,343,729.69, down from $46,407,656.08 in the previous period[40] - The company’s cash and cash equivalents decreased from 38,728,312.77 CNY to 37,848,986.78 CNY[31] - The company received tax refunds amounting to $514,534.27, an increase from $472,652.60 in the prior period[39] - Cash received from other operating activities was $30,000,312.10, compared to $27,800,722.48 previously[39] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥926,696,447.84, reflecting a growth of 17.12% from the end of the previous year[4] - The company’s total liabilities increased by 36.46% to ¥177,576,955.01 due to new short-term borrowings[10] - The total liabilities increased to ¥867,899,865.42 from ¥830,085,133.93, marking a rise of approximately 4.2%[36] - The company’s current liabilities include short-term loans of 177,576,955.01 CNY and accounts payable of 307,108,756.69 CNY[31] - The company’s net assets at the end of 2024 were negative, leading to a continued delisting risk warning despite the removal of other risk warnings[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,499[15] - The largest shareholder, Chongqing Green Development Urban Construction Co., Ltd., holds 12.15% of shares, totaling 95,303,911 shares[15] - The second-largest shareholder, Zhongchi Huicheng Enterprise Management Co., Ltd., holds 5.90% of shares, totaling 46,278,466 shares, which are pledged and frozen[15] - The total equity attributable to shareholders of the parent company improved to ¥22,663,025.18 from a negative equity of ¥54,823,505.99, indicating a recovery in shareholder equity[36] Research and Development - Research and development expenses rose by 108.26% to ¥16,049,011.45, driven by the expansion of the pharmaceutical segment[12] - Research and development expenses rose to ¥16,049,011.45 from ¥7,706,371.33, representing an increase of approximately 108.7%, highlighting a focus on innovation[36] Restructuring and Debt Management - The company is undergoing a pre-restructuring process initiated by creditors due to inability to repay debts and lack of repayment capacity[17] - A total of 3 potential investors submitted applications for restructuring investment, with one investor, Zhi'en Biotechnology Co., Ltd., selected as the final investor[19] - The restructuring plan includes a capital increase of approximately 373,471,302 shares, raising the total share capital to 1,157,634,670 shares[20] - The restructuring investor will acquire 232,000,000 shares at a price of 1.735 RMB per share, resulting in a 20.04% ownership stake[20] - The company plans to hold the first creditors' meeting for the pre-restructuring process on September 29, 2025[21] - The company signed a financial restructuring investment agreement with investors, planning to issue 57 million shares at a price of 1.835 CNY per share, totaling 104,595,000 CNY[22] - The total confirmed debt amount of the company is 760 million CNY, with 75.55 million CNY temporarily unconfirmed and 147,000 CNY not confirmed[23] - The company received a debt waiver of 130 million CNY from creditor Green Development Assets, which will increase the company's capital reserve by the same amount[29] Asset Management - The company’s investment property value increased by 49.40% to ¥185,124,600.00, attributed to the conversion of fixed assets to investment properties[9] - The company transferred 30% equity of its subsidiary, Peak Extreme Intelligent Technology Research Institute, for 5.1 million CNY, with the assessed value of the subsidiary at 14.1917 million CNY[24][25] - The company disposed of fixed assets and received cash of $123,340.00, compared to $32,455,114.00 in the previous period[39] Operating Performance - Total operating revenue for the current period reached ¥284,255,362.94, a significant increase from ¥147,181,487.50 in the previous period, representing an increase of approximately 93.3%[35] - Total operating costs increased to ¥287,027,332.48 from ¥243,077,617.88, reflecting a rise of about 18.1%[36] - Cash paid for taxes was $26,754,351.13, significantly higher than $3,922,515.68 in the prior period[39] - The company paid $37,407,953.95 in employee compensation, a decrease from $61,847,860.27 in the previous period[39]